These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 9428498

  • 1. Nerve lesions after therapy for childhood acute lymphoblastic leukemia.
    Harila-Saari AH, Vainionpää LK, Kovala TT, Tolonen EU, Lanning BM.
    Cancer; 1998 Jan 01; 82(1):200-7. PubMed ID: 9428498
    [Abstract] [Full Text] [Related]

  • 2. Chemotherapy for acute lymphoblastic leukemia may cause subtle changes of the spinal cord detectable by somatosensory evoked potentials.
    Vainionpää L, Kovala T, Tolonen U, Lanning M.
    Med Pediatr Oncol; 1997 Jan 01; 28(1):41-7. PubMed ID: 8950335
    [Abstract] [Full Text] [Related]

  • 3. Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials.
    Harila-Saari AH, Huuskonen UE, Tolonen U, Vainionpää LK, Lanning BM.
    Med Pediatr Oncol; 2001 Mar 01; 36(3):345-51. PubMed ID: 11241435
    [Abstract] [Full Text] [Related]

  • 4. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi AM, Messina C, Mori PG, Miniero R, Colella R, Basso G.
    J Clin Oncol; 1995 Oct 01; 13(10):2497-502. PubMed ID: 7595699
    [Abstract] [Full Text] [Related]

  • 5. Vincristine therapy for children with acute lymphoblastic leukemia impairs conduction in the entire peripheral nerve.
    Vainionpää L, Kovala T, Tolonen U, Lanning M.
    Pediatr Neurol; 1995 Nov 01; 13(4):314-8. PubMed ID: 8771166
    [Abstract] [Full Text] [Related]

  • 6. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Kühl J, Gadner H, Havers W, Plüss H, Kornhuber B, Zintl F, Ritter J, Urban C, Niethammer D, Riehm H.
    Klin Padiatr; 1998 Nov 01; 210(4):192-9. PubMed ID: 9743952
    [Abstract] [Full Text] [Related]

  • 7. Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.
    Stark B, Sharon R, Rechavi G, Attias D, Ballin A, Cividalli G, Burstein Y, Sthoeger D, Abramov A, Zaizov R.
    Cancer; 2000 Jan 01; 88(1):205-16. PubMed ID: 10618625
    [Abstract] [Full Text] [Related]

  • 8. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia.
    Reinders-Messelink HA, Van Weerden TW, Fock JM, Gidding CE, Vingerhoets HM, Schoemaker MM, Göeken LN, Bökkerink JP, Kamps WA.
    Eur J Paediatr Neurol; 2000 Jan 01; 4(5):225-33. PubMed ID: 11030069
    [Abstract] [Full Text] [Related]

  • 9. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up.
    Freeman AI, Boyett JM, Glicksman AS, Brecher ML, Leventhal BG, Sinks LF, Holland JF.
    Med Pediatr Oncol; 1997 Feb 01; 28(2):98-107. PubMed ID: 8986145
    [Abstract] [Full Text] [Related]

  • 10. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
    Nachman J, Sather HN, Cherlow JM, Sensel MG, Gaynon PS, Lukens JN, Wolff L, Trigg ME.
    J Clin Oncol; 1998 Mar 01; 16(3):920-30. PubMed ID: 9508174
    [Abstract] [Full Text] [Related]

  • 11. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory.
    Langer T, Martus P, Ottensmeier H, Hertzberg H, Beck JD, Meier W.
    Med Pediatr Oncol; 2002 May 01; 38(5):320-8. PubMed ID: 11979456
    [Abstract] [Full Text] [Related]

  • 12. [Acute lymphoblastic leukemia in childhood. A 10-year experience with the DFCI 81-01 protocol].
    de Lacerda AF, Chagas M, Neto A, Vieira E, Ribeiro MJ, Pereira F, Ambrósio A, Sousinha M.
    Acta Med Port; 1999 May 01; 12(7-11):287-92. PubMed ID: 10707467
    [Abstract] [Full Text] [Related]

  • 13. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
    Muszyńska-Rosłan K, Konstantynowicz J, Krawczuk-Rybak M.
    Pol Merkur Lekarski; 2007 Oct 01; 23(136):271-5. PubMed ID: 18293849
    [Abstract] [Full Text] [Related]

  • 14. Neurophysiological findings in long-term survivors of acute lymphoblastic leukaemia in childhood treated with the BFM protocol 81 SR-A/B.
    Ueberall MA, Skirl G, Strassburg HM, Wenzel D, Hertzberg H, Langer T, Meier W, Berger-Jones K, Huk WJ, Korinthenberg R, Beck JD.
    Eur J Pediatr; 1997 Sep 01; 156(9):727-33. PubMed ID: 9296540
    [Abstract] [Full Text] [Related]

  • 15. The role of somatosensory evoked potentials in the diagnosis of AIDS-associated myelopathy.
    Tagliati M, Di Rocco A, Danisi F, Simpson DM.
    Neurology; 2000 Apr 11; 54(7):1477-82. PubMed ID: 10751261
    [Abstract] [Full Text] [Related]

  • 16. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
    Kaleita TA, Reaman GH, MacLean WE, Sather HN, Whitt JK.
    Cancer; 1999 Apr 15; 85(8):1859-65. PubMed ID: 10223582
    [Abstract] [Full Text] [Related]

  • 17. [Late sequelae of central nervous system prophylaxis in children with acute lymphoblastic leukemia: high doses of intravenous methotrexate versus radiotherapy of the central nervous system--review of literature].
    Zając-Spychała O, Wachowiak J.
    Med Wieku Rozwoj; 2012 Apr 15; 16(2):128-37. PubMed ID: 22971657
    [Abstract] [Full Text] [Related]

  • 18. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.
    Nishikawa T, Kawakami K, Kumamoto T, Tonooka S, Abe A, Hayasaka K, Okamoto Y, Kawano Y.
    J Pediatr Hematol Oncol; 2008 Jul 15; 30(7):519-21. PubMed ID: 18797198
    [Abstract] [Full Text] [Related]

  • 19. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
    Kumar P, Kun LE, Hustu HO, Mulhern RK, Hancock ML, Coffey D, Rivera GK.
    Int J Radiat Oncol Biol Phys; 1995 Feb 01; 31(3):477-83. PubMed ID: 7852109
    [Abstract] [Full Text] [Related]

  • 20. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, Lutz P, Mechinaud F, Robert A, Boutard P, Marguerite G, Ferster A, Plouvier E, Rialland X, Behard C, Plantaz D, Dresse MF, Philippet P, Norton L, Thyss A, Dastugue N, Waterkeyn C, Vilmer E, Otten J, Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer.
    J Clin Oncol; 2001 Apr 01; 19(7):1935-42. PubMed ID: 11283125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.